Reviva Total Operating Expenses from 2010 to 2025
| RVPHW Stock | USD 0.05 0 3.20% |
Total Operating Expenses | First Reported 2010-12-31 | Previous Quarter 45.4 T | Current Value 47.7 T | Quarterly Volatility 17.9 T |
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 602.5 K or Interest Income of 602.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 20.25. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
Reviva | Total Operating Expenses |
Latest Reviva Pharmaceuticals' Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of Reviva Pharmaceuticals Holdings over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Reviva Pharmaceuticals' Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend |
|
Total Operating Expenses |
| Timeline |
Reviva Total Operating Expenses Regression Statistics
| Arithmetic Mean | 8,289,593,655,273 | |
| Geometric Mean | 21,975,351 | |
| Coefficient Of Variation | 215.80 | |
| Mean Deviation | Huge | |
| Median | 376,860 | |
| Standard Deviation | Huge | |
| Sample Variance | 320014738242050.8T | |
| Range | 47.7T | |
| R-Value | 0.68 | |
| Mean Square Error | 183745299786818.1T | |
| R-Squared | 0.46 | |
| Significance | 0 | |
| Slope | 2,559,748,882,798 | |
| Total Sum of Squares | 4800221073630760T |
Reviva Total Operating Expenses History
About Reviva Pharmaceuticals Financial Statements
Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' Total Operating Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Operating Expenses | 45.4 T | 47.7 T |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.